Futility of antiviral treatments for hepatitis C: An evolving concept entering the direct antiviral agents era

Digestive and Liver Disease

Volumn 45, Issue 5, 2013, Pages 356-361

  Bruno, Savino ^a   Mangia, Alessandra ^b  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

DAA; First generation of protease inhibitors; HCV treatment

Indexed keywords

BOCEPREVIR; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR;

ANTIVIRAL THERAPY; GENETIC POLYMORPHISM; GENOTYPE; HEALTH CARE QUALITY; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN; PRACTICE GUIDELINE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; MEDICAL FUTILITY; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PROTEASE INHIBITORS; TREATMENT OUTCOME;

EID: 84876699164     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.09.011     Document Type: Review

References (19)

1. European Association of the Study of the Liver EASL Clinical Practice Guidelines: Management of hepatitis C. Journal of Hepatology 2011, 55:245-264.
2. Poordad F., McCone J., Bacon B.R., et al. SPRINT-2. Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine 2011, 364:1195-1206.
3. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Advance Telaprevir for previously untreated chronic hepatitis C virus infection. New England Journal of Medicine 2011, 364:2405-2416.
4. Sherman K.E., Flamm S.L., Afdhal N.H., et al. Illuminate study. Response-guided telaprevir combination treatment for hepatitis C virus infection. New England Journal of Medicine 2011, 365:1014-1024.
5. Bacon B.R., Gordon S.C., Lawitz E., et al. HCV RESPOND-2. Boceprevir for previously treated chronic HCV genotype 1 infection. New England Journal of Medicine 2011, 364:1207-1217.
6. Mangia A., Minerva N., Bacca D., et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008, 47:43-50.
7. Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. New England Journal of Medicine 2011, 364:2417-2428.
8. Bruno S, Vierling JM, Esteban R, et al. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV genotype-1 infection and advanced fibrosis/cirrhosis. Journal of Hepatology, submitted for publication.
9. Bacon B., Bruno S., Schiff E., et al. Predictors of sustained virological response (SVR) among poor interferon (IFN) responders when boceprevir (BOC) is added to Pefginterferon alfa-2b/Ribavirin (PR). AASLD 2011, A33.
10. Jacobson I.M., Marcellin P., Zeuzem S., Sulkowski M.S., Esteban R., Poordad F., et al. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology 2012, 56:567-575.
11. Bronowicki J.P., Davis M., Flamm S., et al. Sustained virologic response (SVR) in prior peginterferon/ribavirin (PR) treatment failures after retreatment with boceprevir (BOC)+PR: PROVIDE study interim results. EASL 2012 A 204.
12. Poordad F., Sulkowski M.S., McHutchison J.G., et al. High correlation between week 4 and week 12 as the definition for null response to peginterferon alfa (PEG) plus ribavirin (R) therapy: results from the IDEAL trial. AASLD 2010, A 797.
13. Pol S., Roberts S.K., Andreone P., et al. Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior Peginterferon/Ribavirin treatment failure: sub analysis of the REALIZE Phase III study. AASLD 2011, A 31.
14. Ghany M.G., Nelson D.R., Strader D.B., Thomas D.L., Seeff L.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1433-1444.
15. Lagging M., Duberg A.S., Wejstål R., Weiland O., Lindh M., Aleman S., Josephson F. Group for the Swedish Consensus. Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations. Scandinavian Journal of Infectious Diseases 2012, 44:502-521.
16. Ramachandran P., Fraser A., Agarwal K., et al. UK consensus guidelines for the use of the protease inhibitors. Aliment Pharmacol Ther 2012, 35:647-662.
17. Bruno S., Stroffolini T., Colombo M., et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007, 45:579-587.
18. Bruno S., Crosignani A., Facciotto C., et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010, 51:2069-2076.
19. Hezode C., Dorival C., Zoulim F., et al. Safety of Telaprevir or Boceprevir combination with PegInterferon alfa/Riba in cirrhotic patients: first results of the French program (ANRS CO20-CUPIC). EASL 2012, A 8.